Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
497 hedge funds and large institutions have $14.9B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2020 Q4 according to their latest regulatory filings, with 128 funds opening new positions, 174 increasing their positions, 161 reducing their positions, and 61 closing their positions.
150% more call options, than puts
Call options by funds: $281M | Put options by funds: $112M
110% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 61
15% more funds holding
Funds holding: 433 → 497 (+64)
8% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 161
4% less capital invested
Capital invested by funds: $15.5B → $14.9B (-$588M)
30% less funds holding in top 10
Funds holding in top 10: 33 → 23 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$229M |
| 2 |
BlackRock
New York
|
+$197M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$185M |
| 4 |
State Street
Boston,
Massachusetts
|
+$142M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$100M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$232M |
| 2 |
Renaissance Technologies
New York
|
-$147M |
| 3 |
DM
Deerfield Management
New York
|
-$142M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$129M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$92.2M |
HZNP Hedge Fund Activity: Q4 2020 in Review
497 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2020, worth a combined $14.9B — down 3.8% from $15.5B a quarter earlier.
Buyers outnumbered sellers: 128 funds opened new HZNP positions and 61 closed out — a net gain of 67 holders — while 174 added to existing stakes and 161 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $229M. The largest seller was Fidelity Investments, cutting an estimated $232M.
- 497 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2020, up from 433 in Q3 2020.
- Funds reported $14.9B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2020, down 3.8% quarter-over-quarter.
- 128 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2020 and 61 closed out, a net change of +67 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2020 was Perceptive Advisors, an estimated $229M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2020 was Fidelity Investments, an estimated $232M sold.
Based on aggregated 13F filings for Q4 2020.